...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced studies in medicine >Update on pharmacologic strategies for atrial fibrillation: Rate, rhythm, and beyond
【24h】

Update on pharmacologic strategies for atrial fibrillation: Rate, rhythm, and beyond

机译：心房颤动的药理策略的最新进展：发生率，心律及其他

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To review current management approaches for rate and rhythm control in atrial fibrillation (AF) and to describe potential pharmacologic strategies for the future. EPIDEMIOLOGY: More than 2 million people in the United States have AF and the prevalence is as high as 10% in those over 80 years of age. Stroke risk is increased about 5-fold in those with AF. REVIEW SUMMARY: Atrial fibrillation is common, especially in the elderly, and is associated with significant morbidity and mortality. In particular, the risks of cardioembolic stroke and heart failure are elevated in those with AF. The goals of therapy in AF are to reduce the risk of stroke, AF recurrences, and heart failure. In addition to anticoagulation with aspirin or warfarin, the main options for rate control include calcium channel blockers, β-blockers, digoxin, and atrioventricular node ablation. Maintaining sinus rhythm to reduce symptoms, stroke risk, and progression of adverse atrial remodeling is the other main strategy for AF therapy. TYPE OF AVAILABLE EVIDENCE: Nationally recognized treatment guidelines, randomized controlled studies, retrospective analyses, systematic reviews/meta-analyses. GRADE OF AVAILABLE EVIDENCE: Good (guideline-documented agents used in rate and rhythm control); fair (studies exploring effects of statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in AF). CONCLUSION: Patients with AF have several pharmacologic options for rate or rhythm control in AF. Researchers have recently identified new mechanisms involved in AF and studies may soon lead to new forms of combination therapy that are more effective and safer in preventing onset or recurrences of AF.
机译：目的：审查当前房颤（AF）的速率和心律控制的管理方法，并描述未来的潜在药理策略。流行病学：美国有超过200万人患有房颤，在80岁以上的人群中，患病率高达10％。房颤患者中风风险增加约5倍。综述：房颤是常见的，尤其是在老年人中，并且与明显的发病率和死亡率有关。特别是患有AF的患者会增加心脏栓塞性中风和心力衰竭的风险。 AF的治疗目标是降低中风，AF复发和心力衰竭的风险。除了使用阿司匹林或华法林抗凝外，控制速率的主要选择还包括钙通道阻滞剂，β受体阻滞剂，地高辛和房室结消融。维持窦性心律以减少症状，中风风险和不良心房重构的进展是房颤治疗的另一主要策略。可用证据的类型：全国公认的治疗指南，随机对照研究，回顾性分析，系统评价/元分析。可用证据的等级：良好（用于控制心率和节奏的指南文件）;公平（研究他汀类药物，血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在房颤中的作用的研究）。结论：房颤患者在房颤的发生率或节律控制方面有几种药理学选择。研究人员最近发现了房颤的新机制，研究可能很快会导致新形式的联合治疗，这种新疗法在预防房颤发作或复发方面更加有效和安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号